Abstract
Introduction
Polysaccharides (CHO) are considered T-independent antitype 1 and type 2 on the basis of cytokine secretion and effector function (5). Type 1 responses involve T h 1 cells that gens because of their inability to specifically activate T cells (1). Moreover, the ability to respond to purified CHO is age differentiate in an IL-12 (produced by macrophages) and IFN-γ (produced by NK and T cells) milieu. On the contrary, dependent and children Ͻ18 months usually are unable to mount an anti-CHO antibody response (2). The conjugation type 2 responses involve IL-4-dependent differentiation of T h 2 cells, and are associated with IL-5 secretion and decreased of CHO to a carrier protein improves the immunogenicity because of the T-dependent help conferred by the protein macrophage activation (6).
B and NK cells (8,9) as well as antigen-presenting cells (APC) Unconjugated CHO and CHO-CRM conjugate vaccine were administered in a three-dose schedule (0, 10 and 20 days). (10). When co-administered in experimental animals with proteins or peptides, ISS act as potent adjuvants and induce CHO-TT conjugate vaccine was administered in a two-dose schedule (0 and 14 days). M-ODN or ISS were administered type 1 immune responses (11) even with poor immunogenic antigens (12). Nonetheless, when used to increase an antiin the first inoculum only. Where indicated, CHO-CRM or ISS were used at decreasing concentrations (2.5-0.67 and 40-CHO immune response, ISS not only failed in their adjuvant effect, but significantly reduced the synthesis of anti-CHO 1.25 µg respectively). Unconjugated CHO was also administered i.d. mixed with 4 IU of anti-tetanus vaccine per mouse antibodies (13). This effect was interpreted by the authors as a probable consequence of a B cells polyclonal activation (mix CHO/TT) or s.c. in incomplete Freund's adjuvant (IFA), alone or in combination with ISS. (13). However, at odds with T-independent antigens, the immune response to conjugated CHO relies upon different basis and the use of ISS as adjuvant could influence the Collection of samples amount and the subclasses of anti-CHO antibody produced Plasma was collected by retro-orbital puncture 40 days after following the vaccination.
the first inoculum of CHO or CHO-CRM and 21 days after Haemophilus influenzae type b (Hib) possesses a CHO the first inoculum of CHO-TT, unless specified in selected capsule of polyribosyl ribitol phosphate. Antibodies against experiments. Samples were frozen at -80°C until use. the specific capsular CHO have been shown to be protective against Hib. Several conjugate vaccines, used in infants Evaluation of the immune response during the first year of life, contributed to the decline of incidence of Hib-related diseases (14). The commercially Anti-Hib CHO serum antibody levels were determined by ELISA. A human albumin-conjugated Hib CHO (HSA-CHO; available vaccines use different carrier proteins, such as tetanus toxoid (TT) or diphtheria toxoid (DT).
gift from Chiron) was used at 10 µg/ml in PBS (100 µl/well) to coat flat-bottomed 96-well microtiter plates (Dynatech, In this work, the effect of adding ISS to unconjugated Hib CHO as well as to TT-or cross-reacting material (CRM)-Chantilly, VA) overnight at 4°C. The HSA-CHO conjugate was used to detect anti-CHO antibodies because it binds to the conjugated Hib vaccines was investigated in mice by studying whether ISS may influence the immune response to conjugplates better than unconjugated CHO and does not react with anti-TT or -CRM antibodies elicited by the conjugate vaccines ated CHO. The antibody responses to both the CHO and the carrier as well as anti-CHO-specific IgG subclasses were used. Plates were then incubated for 1 h at 4°C with 2% BSA in PBS (post-coat). Sera (non-immune controls and test sera) evaluated. Furthermore, the cytokines production in mice vaccinated in the presence or absence of ISS and their diluted 1:100 and 2-fold dilutions (1:50-1:3400) of the reference serum in PBS containing 0.2% BSA and 0.1% Tween kinetics of release in the serum was investigated, to obtain evidence of the type 1/type 2 specificity of the immune 20 were added to appropriate wells. After overnight incubation at 4°C and washings, plates were incubated with anti-Ig (IgG response to conjugated CHO. The aims of this study were to contribute to the understanding of the mechanisms involved ϩ IgM ϩ IgA) or anti-IgG (γ chain specific) goat anti-mouse antibodies conjugated with alkaline phosphatase (Southern in the T cell dependency of anti-CHO immune response, and to identify possible advantages of using ISS in the anti-Hib Biotechnology Associates, Birmingham, AL). After a 1 h incubation and washings, p-nitrophenylphosphate (Sigma, vaccination in terms of antibody response against both the CHO and the protein component of a conjugated vaccine.
St Louis, MO) was added as a substrate. The reaction was blocked with 2 M NaOH and the absorbance evaluated at 405 nm using the Microtiter reader Victor-1420 multilabel Methods counter (EG & G/Wallac, Turku, Finland). All tests were designed to compare in the same ELISA plate sera from mice Immunization protocol belonging to different experimental groups. To minimize plateto-plate variations, data were normalized using, as reference Hib CHO and Neisseria meningitidis group A CHO (MenA) were a kind gift from Chiron (Siena, Italy). The DT (CRM 197 )-in each plate, a hyperimmune mouse serum containing antiHib CHO antibody (kind gift from Pasteur Mé rieux MSD) conjugated CHO and the TT-conjugated CHO used were part of the commercially available anti-Hib vaccines (Vaxem Hib; and expressed as ELISA units (EU). Mice were considered responders when the serum anti-CHO EU values were Ͼ2 Chiron and Act-Hib; Pasteur Mé rieux MSD, Lyon, France respectively) as well as the anti-tetanus vaccine (Imovax times the mean EU value of non-immune mice.
To assess the specificity of anti-CHO ELISA, 50 µl of 10-Tetano, Pasteur Mé rieux MSD).
Phosphorotioated CpG ODN and non-ISS-containing ODN fold dilutions (2000-0.0002 pg/ml) of Hib CHO or MenA were added to HSA-CHO-coated plates immediately before 50 µl (M-ODN) were synthesized (M-Medica, Firenze, Italy) according to published sequences (7) (TGACTGTGAACGTTCGAof the reference serum diluted 1:50. The plates were then treated as reported above. GATGA and TGACTGTGAAGCTTCGAGATGA respectively).
Groups (n ϭ 5-10) of female BALB/c or CD1 mice (6-8 The antibody response to the carrier proteins was evaluated as previously described (15). Briefly, TT or CRM were used weeks old; Charles River, Calco, Lecco, Italy) were immunized by intradermal (i.d.) injection of 2.5 µg/mouse of CHO or to coat microtiter plates at 10 µg/ml in carbonate-bicarbonate buffer overnight. After washings and a 1 h post-coat, sera conjugated-CHO (CHO-TT or CHO-CRM) in combination with M-ODN or ISS at 50 µg in a total volume of 50 µl. In diluted 1:100 in PBS-T were added and incubated for 3 h at room temperature. Bound antibodies were detected using some experiments, mice were immunized by s.c. injection. alkaline phosphatase-conjugated goat anti-mouse IgG as described above.
Subclasses of anti-Hib CHO IgG ϩ sera were determined using rat anti-mouse IgG subclass mAb labeled with biotin (PharMingen, San Diego, CA) and horseradish peroxidaseconjugated streptavidin (PharMingen). After the addition of o-phenylenediamine (Sigma fast; Sigma) the reaction was stopped with 2 N H 2 SO 4 and the absorbance was evaluated with the plate reader at 490 nm. A pool of sera from mice vaccinated s.c. with CHO-conjugate vaccine was used as reference serum. In this serum, IgG1 and IgG3 were respectively the most and the least represented anti-CHO IgG subclasses. Thus, 1000 U for IgG1, IgG2a and IgG2b, and 100 U for IgG3 were arbitrarily chosen as anti-CHO subclass contents of the reference serum (16). In each assay 2-fold dilution of the reference serum were tested. The results Groups of CD1 mice were vaccinated i.d. with CHO-TT in the presence or absence of ISS in the first inoculum or treated with 50 µg/mouse of ISS and saline 14 days apart. Three the best when administered twice at the same dose (days mice per group were sacrificed at 6, 24, 48 and 72 h after 0 and 14). Unconjugated CHO failed to induce specific the first and the second inoculation. Sera within each group antibodies, whatever the schedule. were pooled and the kinetics of cytokines secretion evaluated
The influence of ISS was first assessed in BALB/c mice using commercially available ELISA kits (R & D, Minneapolis, vaccinated i.d. with unconjugated or conjugated CHO MN) according to the manufacturer's procedures.
( Table I ). There was a measurable anti-CHO IgG production Statistical analysis when using the conjugate vaccines, but the response was notably increased when the vaccines were administered with Data were expressed as arithmetic mean Ϯ SD and analyzed ISS. In particular, in the CHO-CRM vaccination model, where by the Statview 4.1 program (Abacus Concepts, Berkeley, BALB/c mice responded (CHO-CRM versus non-immune CA). Data were analyzed for normal distribution and the controls: P Ͻ 0.05) constantly with a low anti-CHO IgG statistical significance of the difference between groups was production, the adjuvant effect of ISS was magnified (CHOdetermined by the two-tailed unpaired Student's t-test. Differ-CRM ϩ ISS versus CHO-CRM, P Ͻ 0.001). In the absence ences were considered significant with P Ͻ 0.05.
of ISS, the majority of BALB/c mice vaccinated with CHO-TT showed high levels of anti-CHO IgG, thus rendering less Results evident the adjuvanticity of ISS. The unconjugated CHO was not capable to induce a significant specific response even Anti-CHO antibodies following vaccination with CHO, CHOwhen co-administered with ISS i.d. in saline (Table 1) or s.c.
TT or CHO-CRM in the presence or absence of ISS
in IFA (data not shown). In addition, no anti-CHO response was observed following immunization with the Hib CHO nonMice were immunized with CHO, CHO-CRM or CHO-TT in the presence or absence of ISS and anti-CHO antibodies chemically bound to TT, irrespective on the co-administration of ISS: the CHO/TT mixture resulted in elevated anti-TT (see were detected by ELISA. The use of a protein-conjugated CHO (CHO-HSA) to coat ELISA plates allowed a good and below), but not anti-CHO antibodies. The adjuvant effect of ISS was also tested in the outbred reproducible CHO binding to the plates, and the detection of anti-CHO antibodies without the interference of anti-TT or CD1 mouse strain. Inasmuch as in preliminary experiments CD1 mice showed good immune responses to the CHOanti-CRM antibodies elicited by the conjugated vaccines used. In fact, sera from TT and CRM vaccinated mice did not conjugate vaccines when immunized s.c. and data from the literature indicated the i.d. as the route of injection of ISS react in anti-CHO ELISA (data not shown). Anti-Hib CHO ELISA was specifically inhibited by soluble Hib CHO, but not (26), we chose CD1 mice to test the adjuvant effect of ISS in dependence on the injection route. No significant differences by another polysaccharide such as MenA (Fig. 1A) . The reactivity of the hyperimmune serum used as reference serum in the mean anti-CHO IgG levels were observed following immunization with CHO-conjugate vaccine inoculated i.d. or in all the anti-CHO ELISA is shown in Fig. 1(B) . The titer of this serum corresponded to 1:3200. s.c. (i.d. versus s.c., P Ͼ 0.05), but the number of responding mice was increased when the vaccine was given i.d. (Fig.  In preliminary experiments we determined the optimal dose and schedule for each conjugate vaccine without ISS. CHO-2A). When the effect of ISS was tested in dependence on the administration route, it was observed that the adjuvant activity CRM vaccine gave the best results when administered 3 times (day 0, 10 and 20) at 2.5 µg/mouse, while CHO-TT did was statistically significant only when ISS were administered To determine the influence of ISS on the persistence of versus CHO-CRM, P Ͻ 0.05) (Fig. 3) . At the dose of 10 µg, the increase of IgG levels approached borderline significance specific antibodies, CD1 mice were tested for the anti-CHO IgG levels 120 days after the vaccination (Fig. 2B ). Four (P ϭ 0.0543). months after the vaccination, mice inoculated s.c. showed
Influence of ISS on the dose of CHO-conjugate vaccines mean IgG levels higher than controls, but the effect of ISS on the persistence of specific antibodies was not statistically Preliminary experiment showed that the use of 2.5 µg of CHOsignificant (s.c. and s.c. ϩ ISS versus controls, P Ͻ 0.05; s.c.
conjugate vaccine resulted in the maximal antibody response. versus s.c. ϩ ISS, P ϭ 0.67). On the other hand, when the BALB/c mice were vaccinated with decreasing doses of vaccine was administered i.d., the adjuvant effect of ISS in CHO-CRM, in the presence of 50 µg/mouse of ISS in the first the persistence of specific antibodies was clearly evident inoculum, to verify the adjuvant effect of ISS with lower (Fig. 2B) shown). These data indicate that by the use of ISS the dose Thus, it can be conceived that the i.d. administration is crucial of CHO-CRM vaccine needed to obtain the same levels of for the adjuvant effect of ISS and that ISS administration in serum anti-CHO specific IgG can be reduced to one-fourth. outbred populations increase the frequency of responders to the vaccination.
Influence of ISS on the anti-CHO IgG subclasses detected All together, these data indicate that ISS are effective following s.c. or i.d. immunization with conjugated vaccine adjuvants for CHO-conjugate vaccines. When ISS were co-
The specific IgG subclasses pattern induced by a vaccination administered in the first dose of vaccines, not only was the is indirect evidence for the preferential type 1 or type 2 antibody response more vigorous, but also its persistence immune response evoked by the antigen and/or for the was enhanced. The adjuvant effect was evident in inbred as influence of the adjuvant. ISS are described as inducer of well as in outbred mouse strains, when the i.d. administration type 1 immune response. In this contest, it was interesting to route was used. However, the adjuvant activity of ISS was analyze the IgG subclass production against a classical Tclearly observed only when the CHO was chemically linked independent antigen such as a CHO upon the adjuvant effect to a carrier protein: no anti-CHO antibodies were detected of ISS in the CHO-conjugate vaccine model. When CD1 mice immunizing mice in the presence of ISS with CHO or CHO/ were immunized s.c. in the absence of ISS, IgG1 was the protein vaccine mixtures. main anti-CHO IgG subclass detected (Fig. 4A) TT vaccine in the presence of ISS. In spite of the fact that no anti-CHO IgG was measurable upon vaccination with mixed CHO/TT, the 4 IU anti-tetanus vaccine used in the mixed CHO/TT induced anti-TT antibody levels similar to those obtained with CHO-TT conjugate vaccine. Overall these data release at 24 h, with IL-6 and IFN-γ already detectable at 6 h. indicate that the use of ISS increases the antibody responses At 48 h the serum cytokine level was lower than at 24 h. to both the conjugated CHO and the carrier.
There was a low IFN-γ serum release and a detectable (~10 pg/ml) production of IL-5 at 24 h after the second Influence of ISS on serum cytokine levels in mice vaccinated inoculum (data not shown). ISS given alone induced an with conjugated Hib CHO increasing production of cytokines up to 48 h after the injection, that was mainly characterized by a continuous It has been shown that one of the reasons for the adjuvant effect of ISS is their ability to induce the synthesis of cytokines release of IFN-γ from 6 to 72 h after the first inoculum; no measurable IL-5 was detected (data not shown). The coby APC, B lymphocytes and NK cells. We measured the in vivo cytokine production after the administration of ISS administration of vaccine and ISS caused the release of high cytokine levels already detectable at 6 h. The highest levels alone or the CHO-TT vaccine in the presence or absence of ISS. Table 2 shows the serum cytokine levels in CD1 mice of IL-12 and IFN-γ were respectively observed at 6 and 48 h after the injection. No measurable IL-5 was detected (data treated with CHO-TT vaccine (two doses: day 0 and 14), with ISS (ISS day 0 and saline at day 14) or with CHO-TT vaccine not shown). These data indicate that the i.d. inoculum of ISS induces the systemic release of type 1-defining cytokines and ISS in the first inoculum. Collection of samples started 6 h after the vaccination. Mice immunized with CHO-TT and that the serum release is enhanced when the conjugated vaccine is co-administered. vaccine in the absence of ISS showed a peak of cytokines Concentration of cytokines (pg/ml) in sera from mice following i.d. inoculations of ISS, CHO-TT vaccine or CHO-TT vaccine in the presence of ISS. Sera were collected from independent groups of three mice sacrificed at each indicated time after inoculation. Sera were pooled within each group and tested for cytokines concentration by commercially available ELISA kits.
This finding can be considered as a consequence of a type 1-like immune response (19) induced by ISS. It is remarkable that these IgG subclasses fix the complement (20) and their the production of IL-12 and IFN-γ was greatly increased when ISS was administered together with the CHO-TT vaccine, indicating that ISS and the vaccine have a summative stimulatDiscussion ing activity on the innate immunity (24) . The effects of ISS on the anti-CHO immune response can In this work we investigated the adjuvant role of synthetic ODN containing CpG motifs defined as ISS in the anti-Hib be attributed to the amplification of the T help provided by the carrier. We observed in fact that the increase of anti-CHO vaccination, that is a prototype of CHO-carrier conjugate vaccine. Two commercially available vaccine preparations, antibodies paralleled the increase of anti-carrier antibodies in the presence of ISS. Thus, our data confirm the hypothesis CHO-TT and CHO-CRM, were tested in mice. ISS have been proposed to act as a danger signal that warns of bacterial that after immunization with CHO-carrier conjugate vaccines, anti-CHO-specific B cells precursors receive help by CD4 ϩ infections and activates immune defenses (17). ISS induce activation of APC (10,18) providing the initial cytokine milieu T cells (T h ) that are simultaneously activated by the carrier processed and presented by professional APC. In addition, that sustains the development of type 1 immune responses. Thus, we tested whether the signal provided by ISS might anti-CHO-specific B cells, capturing the conjugate vaccine through the CHO, could process the carrier. CHO-specific B function as adjuvant to induce a type 1-like immune response against Hib CHO. In a previous paper (13), ISS were shown cells could then present epitopes derived from the carrier to carrier-specific T h cells, thus receiving help in a cognate to fail in promoting an anti-CHO immune response. Here we demonstrate that ISS are good adjuvants of the anti-CHO interaction (25) . In any case, spatial and temporal vicinity between CHO-specific B and carrier-specific T cells are response, if a CHO conjugate vaccine is used. Furthermore, while the anti-CHO IgG obtained with the CHO-conjugate required: the activation of the innate immunity and the cytokine milieu induced by ISS were not sufficient to trigger B cells to vaccine were mainly IgG1, in the presence of ISS the additional production of anti-CHO IgG2a and IgG3 was observed.
initiate an anti-CHO antibody production when using uncon- soluble help provided by cytokines (27) .
TT tetanus toxoid
Finally, we showed that the inoculation route is relevant for both the anti-CHO response and the adjuvant effect of ISS. In general, the administration i.d. was shown to be more References effective than the s.c. in inducing anti-CHO antibody and in In conclusion, this study demonstrates that the response
